Status:
TERMINATED
Study of RO6807952 in Patients With Diabetes Mellitus Type 2
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Diabetes Mellitus Type 2
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
Brief Summary
This randomized, double-blind, placebo-controlled, multi-center study will evaluate the efficacy and safety of RO6807952 in patients with diabetes mellitus type 2 inadequately controlled with metformi...
Eligibility Criteria
Inclusion
- Adult patients \>/= 18 and \</=70 years of age
- Diagnosis of diabetes mellitus, type 2 for at least 3 months
- Treated with a stable dose of metformin
- Hemoglobin A1c \>/=7.0% and \</=10.5% at screening
- Fasting plasma glucose \</=240 mg/dL at screening
- Body mass index \>/=27 kg/m2 and \</=42 kg/m2 at screening
- Willing and able to maintain existing diet and exercise habits throughout the study
- C-peptide \>1.5 ng/mL at screening
Exclusion
- History of significant liver or kidney disease
- History of uncontrolled hypertension
- History of significant cardiovascular disease
- History of significant diabetic complications
- History of significant gastrointestinal conditions
- History of weight loss surgery or procedures involving the gastrointestinal tract
- History of chronic or acute pancreatitis
Key Trial Info
Start Date :
November 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2012
Estimated Enrollment :
2 Patients enrolled
Trial Details
Trial ID
NCT01516476
Start Date
November 1 2011
End Date
January 1 2012
Last Update
November 2 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cincinnati, Ohio, United States, 45227